Market Cap
$1.5B
NA
NAMSW
NewAmsterdam Pharma Co N.V.
$12.65 ▲ +0.00%
Prev close $12.65Market cap$1.5B
Biotech & Drug Discovery
Snapshot
The big-picture read on NAMSW right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
SEC Reports
3
Price chart 30d -12.4%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 other
Jun 3, 2026 SEC NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, The Netherlands and MIAMI, Oct. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.
NewAmsterdam Pharma filed an 8-K reporting the results of its 2026 annual general meeting, where shareholders approved t
8-K — Impact 3/10
NewAmsterdam Pharma reported Q1 2026 revenue of $3.0M (flat YoY) and a net loss of $48.4M, widening from $39.5M. The key
8-K — Impact 6/10
NewAmsterdam Pharma's Chief Accounting Officer, Louise Kooij, will depart on August 31, 2026, with a separation agreemen
8-K — Impact 3/10
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
3 SEC filing reports analyzed · 1 bullish, 0 bearish, 0 mixed, 2 neutral · avg impact 4.0/10.
NEUTRAL8-K3/10
NewAmsterdam Pharma filed an 8-K reporting the results of its 2026 annual general meeting, where sha
Jun 3, 2026
BULLISH8-K6/10
NewAmsterdam Pharma reported Q1 2026 revenue of $3.0M (flat YoY) and a net loss of $48.4M, widening
May 7, 2026
NEUTRAL8-K3/10
NewAmsterdam Pharma's Chief Accounting Officer, Louise Kooij, will depart on August 31, 2026, with a
Apr 24, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 2, 2026
other
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, The Netherlands and MIAMI, Oct. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company
Sep 21, 2026
other
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
- First-in-Class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable tolerab
Sep 3, 2026
other
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, The Netherlands and MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Compan
Aug 6, 2026
other
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, The Netherlands and MIAMI, Aug. 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company
Aug 5, 2026
earnings
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
– Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe –
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Next Q | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Current FY | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Next FY | $0.00 | $0.00–$0.00 | — | — | — | $0.1B | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for NAMSW.
Shares short
41
Settlement Sep 15, 2026
Change vs prior
0.0%
Semi-monthly cycle
Days to cover
1.0
At avg daily volume
Of shares outstanding
≈0.0%
Estimate — not % of float
All NAMSW filing & press-release reports (3)
- 8-K reportJun 3, 2026
- 8-K reportMay 7, 2026
- 8-K reportApr 24, 2026